BerGenBio Reports the Data from P-Ib/IIa (BGBC016) Clinical Evaluation of Bemcentinib as 1L Treatment of NSCLC
Shots:
- BerGenBio reported initial results from the P-Ib part of P-Ib/IIa (BGBC016) trial for the treatment of NSCLC
- The P-Ib part aimed at assessing the safety of three escalating doses of bemcentinib + standard chemo-immunotherapy (Keytruda/Carboplatin/Pemetrexed) as a 1L treatment of NSCLC, irrespective of STK11 mutation
- Study showed the required plasma exporsure, similar to the responders in BerGenBio’s BGBC008 study for 2L NSCLC treatment, without any dose-related effect on electrocardiographic changes (QTc); combination was well-tolerated without any new concerns. The P-IIa part is recruiting patients with STK11 mutations
Ref: Bergen Bio | Image: Bergen Bio
Related News:- BerGenBio and Tempus Collaborate to Advance the Development of STK11m to Treat NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
